ReviewAnnals of medicine2025
Mesenchymal stem cell-derived exosomes: a new hope for improving asthma airway remodeling.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma features airway hyperresponsiveness, reversible airflow obstruction, and airway remodeling. Its rising incidence and mortality confer a growing societal burden. Recent studies have revealed the therapeutic potential of mesenchymal stem cell-derived exosomes (MSC-EXOs) for asthma, warranting further investigation into their underlying mechanisms and clinical implications.
objectiveThis review aims to provide a comprehensive summary of the application and underlying mechanisms of MSC-EXOs in mitigating airway remodeling in asthma, with the goal of exploring the feasibility of MSC-EXOs as a potential therapeutic strategy for asthma management.
methodsA comprehensive literature review was conducted using the keywords "Asthma," "Airway Remodeling," "Mesenchymal Stem Cells," and "Exosomes." Relevant studies published between March 17, 2000, and September 24, 2024, were identified through systematic searches in PubMed, Embase, and Web of Science. The retrieved studies were systematically analyzed and organized to offer a thorough and comprehensive overview of the relevant literature.
resultsThis review offers a detailed examination of the pathogenesis of asthma, current therapeutic strategies, and their inherent limitations. It delves into the sources, biological functions, and therapeutic potential of MSCs and MSC-EXOs in mitigating airway remodeling in asthma, along with the molecular mechanisms implicated in these processes. Furthermore, it identifies the limitations of current research on MSC-EXOs therapy for asthma and suggests promising directions for future investigations.
conclusionThis study emphasizes the advantages of MSC-EXOs as a therapeutic modality in the context of regenerative medicine for asthma treatment. Preclinical studies have consistently demonstrated the therapeutic potential of MSC-EXOs, suggesting that they may provide additional treatment options for asthma patients in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.